Aurobindo Pharma leads the gainer list of ‘BSE Health Care’ space

Aurobindo Pharma is currently trading at Rs. 84.70, up by 2.35 points or 2.85% from its previous closing of Rs. 82.35 on the BSE.

The scrip opened at Rs. 82.25 and has touched a high and low of Rs. 85.90 and Rs. 81.80 respectively. So far 3,63,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 275.00 on 05-Jan-2011 and a 52 week low of Rs. 80.35 on 18-Nov-2011.

Last one week high and low of the scrip stood at Rs. 113.65 and Rs. 80.35 respectively. The current market cap of the company is Rs. 2,465.00 crore.

The promoters holding in the company stood at 54.36% while Institutions and Non-Institutions held 31.77% and 13.87% respectively.

Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like USFDA, UKMHRA, WHO, Health Canada, MCC South Africa, TGA Australia, ANVISA Brazil.

The Company reported net loss of Rs 41.88 crore for the quarter ended September 30, 2011 as compared to net profit Rs 214.03 crore for the corresponding quarter of the previous year. Company’s total income for the second quarter of the fiscal 2011-12 has decreased by 8.89% at Rs 959.41 crore from Rs 1053.04 crore in the corresponding quarter of the fiscal 2010-11. On consolidated basis, the Group reported net loss of Rs 80.16 crore for the quarter under review as compared to net profit of Rs 198.32 crore for the quarter ended September 30, 2010. Its total income has slipped by 3.73% to Rs 1081.27 crore for the quarter ended September 30, 2011 from Rs 1123.20 crore for the quarter ended September 30, 2010.

Further, the company reported that its first half of the current fiscal has been challenging on account of lower formulation sales, full impact of the US FDA alert on its Unit VI Cephalosporin manufacturing facility, subdued demand environment in Europe, disruption in operations due to regional unrest and notional loss on restatement of foreign currency borrowings. However, the company is confident to deliver on better operational performance in the coming quarters with profitable sales mix.

The consolidated financials include results of all the subsidiaries and joint ventures. During the quarter, Aurobindo Pharma (Bulgaria), a stepdown subsidiary of the company, was liquidated and ceased to be a subsidiary